NFKB1 and osteosarcoma: A novel bone‐targeted fluorous NBD nanoparticle (DN‐F) effectively inhibits osteoclast differentiation and osteosarcoma growth by disrupting the NF‐κB signaling pathway, demonstrating enhanced bone‐targeting and suppression of bone destruction, while providing a versatile platform for future peptide‐based nanomedicines.